Charles Schwab Investment Management Inc. Buys 296,012 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Teva Pharmaceutical Industries by 28.8%, owning a total of 1,324,936 shares valued at approximately $20.4 million after acquiring an additional 296,012 shares.
• Several institutional investors, including Mariner LLC and MetLife Investment Management, have also increased their stakes in Teva during the last quarter, reflecting growing interest in the company's stock.
• Teva recently reported an earnings per share (EPS) of $0.66 for the last quarter, exceeding analysts' expectations, but its revenue fell slightly short of projections, indicating mixed financial performance.

Charles Schwab Investment Management Inc. boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 28.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,324,936 shares of the company's stock after purchasing an additional 296,012 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.12% of Teva Pharmaceutical Industries worth $20,364,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TEVA. Mariner LLC increased its holdings in shares of Teva Pharmaceutical Industries by 10.6% in the fourth quarter. Mariner LLC now owns 59,356 shares of the company's stock worth $1,308,000 after purchasing an additional 5,689 shares during the last quarter. NewEdge Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 12.6% during the 4th quarter. NewEdge Advisors LLC now owns 35,482 shares of the company's stock valued at $782,000 after buying an additional 3,983 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Teva Pharmaceutical Industries by 13.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,611,743 shares of the company's stock worth $57,568,000 after acquiring an additional 313,817 shares during the last quarter. MetLife Investment Management LLC increased its stake in Teva Pharmaceutical Industries by 40.4% in the 4th quarter. MetLife Investment Management LLC now owns 133,425 shares of the company's stock worth $2,941,000 after acquiring an additional 38,400 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of Teva Pharmaceutical Industries by 33.3% during the 4th quarter. Stifel Financial Corp now owns 88,478 shares of the company's stock worth $1,950,000 after acquiring an additional 22,087 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TEVA. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective for the company. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Trading Up 6.7%

Shares of TEVA opened at $18.7920 on Friday. The company's fifty day simple moving average is $16.72 and its 200-day simple moving average is $16.27. The company has a market cap of $21.55 billion, a P/E ratio of -117.45, a P/E/G ratio of 1.04 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm's revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Buying and Selling

In other news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. In the last three months, insiders sold 65,001 shares of company stock valued at $996,958. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.